Muhammad Iqbal Bhatti, Ashraf Sokker, Kenneth B. Jones, Mariam Baig, Parv Sains, Muhammad S Sajid
2018
0
en
6
— Terkait
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G. Altman, the PRISMA Group*
Annals of Internal Medicine · American College of Physicians
Academia and Clinic18 August 2009Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementFREEDavid Moher, PhD, Alessandro Liberati, MD, DrPH, Jennifer Tetzlaff, BSc, and Douglas G. Altman, DSc, the PRISMA Group*David Moher, PhDFrom Ottawa Methods Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada; Università di Modena e Reggio Emilia, Modena, Italy; Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy; and Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.Search for more papers
David Moher, A. Liberati, Jennifer Tetzlaff, Douglas G. Altman, for the PRISMA Group
BMJ · BMJ
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number Flow of information through the different phases of a systematic review No of records identified through database searching No of additional records identified through other sources No of records after duplicates removed No of studies included in qualitative synthesis No of studies included in
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G. Altman, The PRISMA Group
PLoS Medicine · Public Library of Science
se ha posicionado como un centro de referencia asistencial y académica, con la proyección de conformar clínicas o centros de excelencia.Para lograr este objetivo, es indispensable que realice y se ciña a sus propias guías de práctica clínica o estándares clínicos basados en la evidencia (ECBE), que permita una adecuada y estandarizada atención de pacientes aplicando la mejor evidencia médica disponible.La obesidad es una patología de alta prevalencia en la población general, siendo uno de los motivos de consulta más
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi et al.
Hepatology · Lippincott Williams & Wilkins
Potential conflict of interest: Dr. Chalasani consults for and received grants from Eli Lilly. He consults for NuSirt, AbbVie, Afimmune, Tobira, Madrigal, Shire, Cempra, Ardelyx, Axovant, and Amarin. He received grants from Intercept, Gilead, Galectin, and Cumberland. Dr. Younossi consults for Bristol‐Myers Squibb, Gilead, Intercept, Allergan, and GlaxoSmithKline. He advises for Vertex and Janssen. Dr. Brunt advises for Gilead. Dr. Charlton consults for and received grants from Gilead, Intercept, NGM Bio, Genfit, and Novartis. He received grants from Conatus. Dr.
Eric Van Cutsem, Andrés Cervantes, Bernard Nordlinger, Dirk Arnold
Annals of Oncology · Elsevier BV
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet‐Tieulent et al.
CA A Cancer Journal for Clinicians · Wiley
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has